marrow failure causing overwhelming sepsis, multiorgan failure, or gastrointestinal bleeding. [4] [5] [6] GVHD that presents exclusively with cutaneous manifestations carries a better prognosis. 2 LTxassociated GVHD is diagnosed on the basis of clinical symptoms, along with evidence of macrochimerism (>1% donor cells) in the bone marrow or skin. 3 Although a diagnostic skin biopsy is typically performed, the histological picture is not pathognomonic for acute GVHD. Various treatment modalities are driven by insights into the pathophysiological mechanism of GVHD. The treatment options are largely in line with the approaches for GVHD after allogeneic hematopoietic stem cell transplant. 7 Initial treatment typically includes the use of a corticosteroid for its lympholytic, immunosuppressive, and anti-inflammatory effects; increase in the immunosuppressive regimen (to inhibit the donor anti-host reaction); or tapering, discontinuation, or change of type of immunosuppressive medication (to enhance host anti-donor reactivity). All other medications with potentially myelosuppressive actions are reduced or discontinued, while antimicrobial prophylaxis is instituted. Various regimens have been reported, but results are mixed, and a uniformly effective treatment protocol is not available. In the past decade, however, novel approaches such as monoclonal antibody (mAb) therapy have been increasingly explored in an effort to reduce the high mortality rate. Specifically, the use of mAb that targets key players in the pathophysiology of GVHD, 7 such as T lymphocytes by means of anti-interleukin 2 (IL-2) receptor (IL2R) antibodies (IL2RAb) 8, 9 or the inflammatory mediator tumor necrosis factor (TNF)-α by means of anti-TNF-α antibodies (TNFAb), 10 has been reported. Given the rarity of the condition, however, evidence largely stems from single case reports and small case series with variable and/or unknown follow-up times, and the efficacy of these new therapies for LTxassociated acute GVHD remains unclear. In a recent literature review on the epidemiology and clinical presentation of GVHD after LTx, Murali et al performed a descriptive analysis of reported mortality rates and found that mortality rates lower than 60% were found only when grouping cases and small series of patients treated with mAb targeting IL2R, TNF-α, or CD2. 4 At our transplant center, with more than 25 years' of experience of LTx, we documented acute GVHD in 5 of 1355 patients, establishing an incidence of 0.36%. Here, we describe our 5 patients with LTxassociated GVHD, perform a systematic literature review, and evaluate the potential benefit of mAb and more in particular of anti-TNF-α and anti-IL-2 antibodies treatment on the aggregated patient survival.
| MATERIAL S AND ME THODS

| Retrospective single-center analysis
We performed a retrospective analysis of our collective LTx database from December 1989 to December 2017 and identified and reviewed the case records of all patients presenting with histologically (skin and bone marrow) confirmed acute GVHD. We systematically retrieved data on recipient demographics (age, gender, blood group, and etiology of liver cirrhosis), presenting symptoms, time from transplant to symptoms and time from symptoms to diagnosis, diagnosis, treatment and response, and outcome after GVHD.
| Systematic literature review
A systematic literature search was performed in PubMed MEDLINE (January 1960 to January 2018) and EMBASE (January 1960 to January 2018) with the MeSH search criteria "liver transplant" and "GVHD." Titles and abstracts were screened to determine if the report met the inclusion criterion, being "any report on 1 or more patients, older than 18 years, who received a LTx and developed acute GVHD within 100 days post-transplant." If the abstracts
showed that the article met the inclusion criterion, the full-text manuscript was retrieved for further study. To supplement the electronic database search, we manually checked the reference lists of the identified articles and followed the same strategy. The initial search yielded 292 publications ( Figure 1 
Records idenƟfied through database searching (n = 288)
Records aŌer duplicates removed (n = 284)
Records screened (n = 284)
Records excluded (n = 206)
Full-text arƟcles assessed for eligibility (n = 77)
Full-text arƟcles excluded (n = 0)
Studies included in systemaƟc review (n = 77) ) and patients receiving IL2RAb treatment (daclizumab or basiliximab 12, 13, [53] [54] [55] 66 ). The treatment regimens in the no-mAb group consisted of corticosteroids, cyclosporine, mycophenolate mofetil, tacrolimus, Muromonab-CD3 (OKT3), and ATG. Although OKT3 is an mAb, we classified this treatment under the no-mAb group because toxicity has rendered its use obsolete.
| Statistical analysis
All analyses have been performed by using SAS software, version 9.4 of the SAS System for Windows.
| RE SULTS
| Retrospective single-center analysis
Of 1355 consecutive LTx recipients at our center between December 1989 to December 2017, we identified 5 patients with histologically confirmed GVHD (Table 1) , establishing an incidence of 0.36%.
Three patients received mAb treatment: infliximab and basiliximab (patient 1), daclizumab (patient 2), and basiliximab followed by rituximab (patient 3 
| Patient 3
A 63-year-old man was transplanted for alcohol-related liver cirrho- 
| Systematic literature review
Our literature search identified 150 adult patients with LTxassociated GVHD, reported between 1990 and January 2018. The literature review is summarized in Table 2 . Fifty-seven reports concerned 1 case report, 20 small case series reports described 2 to 8 patients, and 1 study described 13 patients.
| Aggregated data analysis
Adding our current series of 5 patients yielded a total study population of 155 patients. In 24 (15.5%) of 155 patients, the treatment included mAb therapy, 4 patients (2.6%) received anti-TNFAb and 17 patients (11%) received IL2RAb; of these, 1 patient received a combination of the 2 (basiliximab followed by alemtuzumab); 1 patient received rituximab in combination with prednisolone and ATG (Table 3) . The remaining 131 patients (84.5%) received other types of treatment, including corticosteroids, cyclosporine, mycophenolate mofetil, tacrolimus, OKT3, and/or ATG.
In the mAb-treated group, the actual reported patient survival (within varying or unknown study follow-up periods) was statistically significantly higher than in the no-mAb group: 11/24 (46%) vs 27/131 (21%), P = .018 (Table 4 ). In the TNFAb group, the actual reported patient survival was statistically significantly better than that of the no-mAb group: 3/4 (75%) vs 27/131 (21%), P = .03 (Table 4 ). After removal of 5 OKT3-treated patients from the nomAB group, the result remained similar: 11/24 (46%) vs 25/126 (20%), P = .01.
In the IL2RAb group, the actual reported patient survival was statistically significantly better than that of the no-mAb group: 8/17 (47%) vs 27/131 (21%), P = .029 (Table 4 ).
| D ISCUSS I ON
Acute GVHD after LTx is rare but carries an extremely poor prognosis. The published literature is heterogeneous in nature and composed predominantly of case reports and small case series, hampering our understanding of how to develop treatment algorithms that may improve the outcome of this condition. 2, 3 The potential value of biological therapies, which increasingly find their way into the treatment of GVDH after hematopoietic cell transplant, is especially poorly understood. 7 Here, we report on our clinical experience with LTx-associated GVHD and provide a systematic review of the published literature; by applying Fisher exact tests on the aggregated data, we provide the first cautious evidence that mAb treatment targeting TNF-α and IL2R may be beneficial in LTx-associated acute GVHD.
In their excellent recent review on the epidemiology and clinical presentation of GVHD after LTx, Murali et al suggested a promising role for mAb treatment. They performed a descriptive analysis of reported mortality rates according to treatment type and found rates to be >70% for 17 of 20 different treatment regimens, whereas rates <60% were found in patients treated with mAb targeting TNF-α, IL2R, and CD2. 4 Whereas this review concerned not only patients with acute GVHD but also patients with chronic GVHD, which tends to be milder in course, our study concerned patients with acute GVHD only. In addition, based on Fisher exact tests, significant differences in survival were observed between mAb and non-Ab patients, also when evaluating the specific groups of IL2RAb and TNFAb. Obviously, this result needs to be interpreted with caution becausee these comparisons ignore the differences in follow-up times between patients and between studies. Regretfully, studies failed to report the survival times of the nondeceased patients, and 2 studies even did not give information on the event times of the deceased patients. As a result, it was not feasible to use the appropriate survival analysis technique for group comparisons (ie, the exact log rank test). 88 We have performed some sensitivity analyses based on imputation of the unknown censoring and event times. The aim was to verify if the superiority of mAb was confirmed when using the available event time information and incorporating uncertainty about the missing event times. Results of these analyses yielded similar conclusions (results not shown/details can be found in supplementary material).
The incidence of LTx-associated GVHD in our practice was 0.4%, which is close to the incidence reported in the literature.
1,3
With 3 of 5 patients having received mAb treatment, the proportion at our center is relatively high. One patient was given TNF inhibitors and anti-IL2R inhibitors and is alive 2 years after transplant. Similarly, for the 4 patients reported in the literature to have had TNF-α-inhibition treatment, the reported survival rate was high (75%). 66, 71, 73, 74 The 2 other patients from our series who received mAb treatment died from GVHD. Other series found mortality rates, ranging from 68% to 83%. 15, 54, 57, 72, 73, 76, 89 As mentioned, the skin and small bowel are the most commonly affected organs in LTx-associated GVHD. 90 In contrast to hematopoietic stem cell recipients with GVHD, liver dysfunction is typically absent in LTx-associated acute GVHD, 
45-116
The question mark indicates "data not available" or "data not reported in manuscript." anti-IL2R, anti-IL2 receptor antagon; anti L-AB, anti-lymphocyte antibody; ATG, anti-thymocyte globulin; AZA, azathioprine; BMS, Bone Marrow Suppression; CNI, calcineurin inhibitors; CsA, cyclosporine A; Cyclo, cyclosporine A; FK, tacrolimus; G-CSF, Granulocyte-colony stimulating factor; GI, Gastrointestinal Bleeding; GM-CSF, Granulocyte/Macrophage Colony Stimulating Factor; IS, immunosuppression; IVIG, Intravenous immune globulin; MMF, mycophenolate mofetil; OKT3, Muromonab-CD3; PSL, prednisolone; SCT, stem cell transplantation..
TA B L E 2 (Continued)
is as yet unavailable. Not surprisingly, the 6-month mortality has been reported to be similar in patients receiving stronger or weaker immunosuppressive therapy. 4 In selected treatmentresistant patients, immunotherapy with mesenchymal stromal cells (MSCs) 91 and haploidentical hematopoietic stem cell transplant has been applied. 65 The Reportedly, a number of risk factors for GVHD after LTx have been described, including HLA matching, 71 Etiology of liver disease was reported in 123 total cases; organ involvement was reported in 124 cases.
GVHD after hematopoietic stem cell transplant, mAb therapy has been introduced with better response rates compared with steroids or to treat steroid-refractory acute GVHD.
95-97
The use of OKT3 was reported in 5 cases. Eventually we decided not to classify OKT3 as a mAb because (1) of its major reported toxicity, (2) its use is obsolete, and (3) of its mechanism of action and the historically anticipated effect to increase immunosuppression in order to treat acute GVHD. Also, its mechanism of action does not specifically target the 3-phase model of GVHD pathophysiology, in contrast to the mAb group. Last, whether OKT3-treated patients were excluded from the analysis does not change the outcome.
Although our review represents a substantially large population of patients, we recognize that the study has certain limitations.
Inherent to the exceptionally low incidence of the condition, the study design was retrospective and covered mostly empirical evidence from case reports and small case series. In consequence, the patient population was also heterogeneous with a large variation in preparatory regimens, posttransplant immunosuppressive regimens, and first-or second-line GVHD treatment regimens. Because of the nature of reporting so far, data on actual follow-up times for censored patients were not available. However, the uncertainty about the missing censoring times was addressed by repeating the analysis on multiple imputed data sets. Furthermore, because of the type of studies available, the data were pooled without taking potential study effects into consideration. Because mAb treatment is offered as a second-or third-line treatment, there is a risk of survivor bias.
These patients lived long enough to receive the treatment and therefore may have been less ill. Last, because of its low incidence, one can assume that LTx-associated GVHD is underdiagnosed and underreported, presenting a potential publication bias. For example, it can be assumed that fatal cases of GVHD are less likely to be published or physicians who treat patients with mAb therapy are more likely to publish the case if the treatment is successful. In the near future, an international registry on LTx-associated GHVD, its treatment and survival, might be a first but important step to develop an effective treatment.
Despite the difficulty of interpreting the fragmented and empirical evidence on LTx-associated GVHD and the limitations this brings to our study, our data provide a first indication that mAb treatment might provide extra therapeutic benefit. Currently, mAb treatment in LTx-associated GVHD is being offered as second-or third-line treatment only. The exceptionally poor prognosis could justify introducing such treatment as a first-line strategy. 
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